Souhaitez-vous accéder aux communiqués récents ?

Idorsia nominates three Board Directors with outstanding pharmaceutical industry, management and financial expertise for election at the Annual General Meeting 2026 on May 6, 2026All Board members –...

Dublin, March 23, 2026 (GLOBE NEWSWIRE) -- The "Oncology Clinical Trials Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's...

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

TORONTO, March 20, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that St. Michael’s Hospital (SMH), part of Unity...

Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population...

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...

San Mateo, California, March 19, 2026 (GLOBE NEWSWIRE) -- SnapLogic, the Agentic Integration Company, today announced it has been positioned by Aragon Research, Inc. in the Leader section of the...

San Mateo, California, March 18, 2026 (GLOBE NEWSWIRE) -- SnapLogic, the Agentic Integration Company, today announced that it has been named as a Visionary by Gartner in the Magic Quadrant for...

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmology First patient enrollment anticipated in Q2 2026 SOLANA BEACH,...

ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company...